Hyaluronan-decorated copper-doxorubicin-anlotinib nanoconjugate for targeted synergistic chemo/chemodynamic/antiangiogenic tritherapy against hepatocellular carcinoma
Copyright © 2024 Elsevier Inc. All rights reserved..
Copper-based nanomaterials show considerable potential in the chemodynamic therapy of cancers. However, their clinical application is restricted by low catalytic activity in tumor microenvironment and copper-induced tumor angiogenesis. Herein, a novel copper-doxorubicin-anlotinib (CDA) nanoconjugate was constructed by the combination of copper-hydrazide coordination, hydrazone linkage and Schiff base bond. The CDA nanoconjugate consists of a copper-3,3'-dithiobis(propionohydrazide)-doxorubicin core and an anlotinib-hyaluronan shell. Benefiting from hyaluronan camouflage and abundant disulfide bonds and Cu2+, the CDA nanoconjugate possessed excellent tumor-targeting and glutathione-depleting abilities and enhanced chemodynamic efficacy. Released doxorubicin significantly improved copper-mediated chemodynamic therapy by upregulating nicotinamide adenine dinucleotide phosphate oxidase 4 expression to increase intracellular H2O2 level. Furthermore, the nanoconjugate produced excessive •OH to induce lipid peroxidation and mitochondrial dysfunction, thus greatly elevating doxorubicin-mediated chemotherapy. Importantly, anlotinib effectively inhibited the angiogenic potential of copper ions. In a word, the CDA nanoconjugate is successfully constructed by combined coordination and pH-responsive linkages, and displays the great potential of copper-drug conjugate for targeted synergistic chemo/chemodynamic/antiangiogenic triple therapy against cancers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:662 |
|---|---|
| Enthalten in: |
Journal of colloid and interface science - 662(2024) vom: 15. März, Seite 857-869 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tan, Gang [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.03.2024 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcis.2024.02.085 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368723860 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368723860 | ||
| 003 | DE-627 | ||
| 005 | 20240313234419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcis.2024.02.085 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM368723860 | ||
| 035 | |a (NLM)38382370 | ||
| 035 | |a (PII)S0021-9797(24)00329-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tan, Gang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hyaluronan-decorated copper-doxorubicin-anlotinib nanoconjugate for targeted synergistic chemo/chemodynamic/antiangiogenic tritherapy against hepatocellular carcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2024 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a Copper-based nanomaterials show considerable potential in the chemodynamic therapy of cancers. However, their clinical application is restricted by low catalytic activity in tumor microenvironment and copper-induced tumor angiogenesis. Herein, a novel copper-doxorubicin-anlotinib (CDA) nanoconjugate was constructed by the combination of copper-hydrazide coordination, hydrazone linkage and Schiff base bond. The CDA nanoconjugate consists of a copper-3,3'-dithiobis(propionohydrazide)-doxorubicin core and an anlotinib-hyaluronan shell. Benefiting from hyaluronan camouflage and abundant disulfide bonds and Cu2+, the CDA nanoconjugate possessed excellent tumor-targeting and glutathione-depleting abilities and enhanced chemodynamic efficacy. Released doxorubicin significantly improved copper-mediated chemodynamic therapy by upregulating nicotinamide adenine dinucleotide phosphate oxidase 4 expression to increase intracellular H2O2 level. Furthermore, the nanoconjugate produced excessive •OH to induce lipid peroxidation and mitochondrial dysfunction, thus greatly elevating doxorubicin-mediated chemotherapy. Importantly, anlotinib effectively inhibited the angiogenic potential of copper ions. In a word, the CDA nanoconjugate is successfully constructed by combined coordination and pH-responsive linkages, and displays the great potential of copper-drug conjugate for targeted synergistic chemo/chemodynamic/antiangiogenic triple therapy against cancers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antiangiogenesis | |
| 650 | 4 | |a Drug nanoconjugate | |
| 650 | 4 | |a Hyaluronic acid | |
| 650 | 4 | |a Reciprocal chemodynamic chemotherapy | |
| 650 | 4 | |a Self-assembly | |
| 650 | 7 | |a Copper |2 NLM | |
| 650 | 7 | |a 789U1901C5 |2 NLM | |
| 650 | 7 | |a anlotinib |2 NLM | |
| 650 | 7 | |a Hyaluronic Acid |2 NLM | |
| 650 | 7 | |a 9004-61-9 |2 NLM | |
| 650 | 7 | |a Nanoconjugates |2 NLM | |
| 650 | 7 | |a Hydrogen Peroxide |2 NLM | |
| 650 | 7 | |a BBX060AN9V |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Glutathione |2 NLM | |
| 650 | 7 | |a GAN16C9B8O |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 650 | 7 | |a Quinolines |2 NLM | |
| 700 | 1 | |a Hou, Guanghui |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Junmin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yaping |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Weijun |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Wenjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaobing |e verfasserin |4 aut | |
| 700 | 1 | |a Suo, Aili |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of colloid and interface science |d 1966 |g 662(2024) vom: 15. März, Seite 857-869 |w (DE-627)NLM041487958 |x 1095-7103 |7 nnns |
| 773 | 1 | 8 | |g volume:662 |g year:2024 |g day:15 |g month:03 |g pages:857-869 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcis.2024.02.085 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 662 |j 2024 |b 15 |c 03 |h 857-869 | ||